Latest Anemia News
Both hepcidin-25 levels and the hepcidin/ferritin ratio were significantly higher in patients on peritoneal dialysis vs hemodialysis.
Use of erythropoiesis-stimulating agents to treat anemia in patients with non-dialysis-dependent chronic kidney disease has been decreasing since the October 2009 publication of TREAT results.
Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL.
Epoetin dose is significantly associated with cardiovascular disease whether patients had lower or higher hemoglobin levels, study finds.
In a study, IV iron was associated with twice the risk for infections in CKD.
Randomized controlled trial finds no significant difference between high- and low-dose intravenous iron with respect to mortality, non-fatal cardiovascular outcomes, and infection.
In a study, patients received half the amount of iron during the reduced dosing period: 126.6 vs 51.2 mg/month.
Peritoneal dialysis patients with MCV of 96 fl or more had a 29% greater risk for early death compared with a reference group.
Restoration of iron homeostasis and normal hepcidin levels appears to play a key role in freeing hemodialysis patients from having to receive erythropoiesis-stimulating agents.
Time-averaged hemoglobin levels, not hemoglobin cycling, is associated with an increased risk of left ventricular hypertrophy in pediatric dialysis patients, a study found.
Japanese post-marketing study identified no new safety concerns among patients with non-dialysis chronic kidney disease treated with darbepoetin alfa and followed up for 3 years.
In a Spanish study, endoscopic evaluation of patients with CKD and anemia revealed that 68.2% of patients had at least 1 gastrointestinal lesion.
New study "adds to the evidence of obesity-associated advantages," researchers conclude.
In a small study, intermittent vs continuous administration of IV iron resulted in less hemoglobin variability in hemodialysis patients with anemia.
Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients